What are the best treatments for Muscular dystrophy?

There is currently no cure for muscular dystrophy, so treatment focuses on managing symptoms, maintaining mobility, and improving quality of life through a multidisciplinary approach. Standard care typically involves corticosteroid therapy to preserve muscle strength, combined with aggressive physical therapy, respiratory support, and cardiac monitoring to address the systemic nature of the condition.

What are the primary pharmacological treatments for muscular dystrophy?

Management of muscular dystrophy is highly individualized based on the specific genetic subtype, such as Duchenne, Becker, or Limb-Girdle. For many forms of muscular dystrophy, corticosteroids like prednisone or deflazacort (Emflaza) remain the standard first-line medication to help slow the progression of muscle weakness and preserve pulmonary function. In recent years, precision medicine has introduced exon-skipping therapies for specific mutations in Duchenne muscular dystrophy, such as eteplirsen (Exondys 51), golodirsen (Vyondys 53), and viltolarsen (Viltepso). These treatments are designed to bypass genetic "typos," though they are only applicable to a subset of patients.

What non-pharmacological therapies are essential for patient care?

Because muscular dystrophy affects multiple body systems, non-pharmacological interventions are just as critical as medication. These therapies aim to prevent contractures, optimize independence, and manage secondary complications. Key components of a comprehensive care plan include:

• Physical Therapy: Regular stretching and range-of-motion exercises to prevent joint contractures and maintain muscle flexibility.


• Occupational Therapy: Adapting the home and work environment with assistive devices to maximize daily functioning.


• Respiratory Care: Monitoring lung capacity and utilizing assisted ventilation or cough-assist devices as muscle weakness progresses.


• Orthopedic Intervention: Surgical procedures, such as spinal fusion for scoliosis or tendon releases, to improve comfort and posture.


• Cardiac Monitoring: Regular echocardiograms and EKGs, as cardiomyopathy is a common complication in many types of muscular dystrophy.

What is the role of a multidisciplinary care team?

Effective management of muscular dystrophy requires a coordinated team of specialists. Because the disease is systemic, no single physician can address every aspect of care. A typical multidisciplinary team includes a neurologist (specializing in neuromuscular disorders), a cardiologist, a pulmonologist, a physical medicine and rehabilitation (physiatrist) specialist, and a physical therapist. At DiseaseMaps.org, 207 people with muscular dystrophy have shared their experiences, often highlighting the importance of early coordination between these specialists to prevent long-term complications.

Are there emerging treatments or clinical trials?

The field of research for muscular dystrophy is rapidly evolving. Current clinical trials are investigating gene replacement therapies, which aim to deliver a functional copy of the missing or mutated gene into muscle cells. Other research focuses on anti-fibrotic drugs designed to prevent the scarring of muscle tissue. Patients interested in these experimental options should discuss clinical trial eligibility with their primary neurologist, as these studies often have strict inclusion criteria based on age, genetic mutation, and current ambulatory status.

Next steps

• Consult a neuromuscular specialist to ensure your treatment plan is tailored to your specific genetic diagnosis.


• Schedule baseline cardiac and pulmonary evaluations to establish a standard for future monitoring.


• Connect with the community at DiseaseMaps.org to learn how others manage daily symptom progression.


• Search ClinicalTrials.gov to see if your specific type of muscular dystrophy is currently part of a gene therapy or pharmaceutical trial.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider regarding your specific treatment needs.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Muscular Dystrophy Overview.


• Orphanet: Rare Disease Database for Neuromuscular Disorders.


• Muscular Dystrophy Association (MDA): Clinical Care Guidelines.


• OMIM (Online Mendelian Inheritance in Man): Genetic basis of muscular dystrophies.